

Title: Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

Short title: Sex differences and antipsychotics

Journal: CNS Drugs

Authors:

Megan Galbally^{1,2} ORCID [0000-0003-3909-1918](https://orcid.org/0000-0003-3909-1918)

Karen Wynter^{1,3} ORCID [0000-0003-4620-7691](https://orcid.org/0000-0003-4620-7691)

Dan Siskind^{4,5} ORCID [0000-0002-2072-9216](https://orcid.org/0000-0002-2072-9216)

Christoph U. Correll^{6,7,8,9} ORCID [0000-0002-7254-5646](https://orcid.org/0000-0002-7254-5646)

Korinne Northwood^{4,5} ORCID [0000-0001-6268-547X](https://orcid.org/0000-0001-6268-547X)

Susanna Every-Palmer¹⁰ ORCID [0000-0001-6455-9741](https://orcid.org/0000-0001-6455-9741)

Affiliations:

1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

Address Correspondence to: Professor Megan Galbally, megan.galbally@monash.edu

Supplementary Table 3: Change in PANSS scores (Baseline to End of Phase) by sex, within each treatment group

		Total n	Females			Males			<i>p</i> ¹	<i>d</i>
			Mean	SD	n	Mean	SD	n		
Olanzapine	Total score	239	-8.39	18.12	70	-5.93	15.81	169	0.223	0.079
	Positive Scale	239	-2.66	5.11	70	-2.33	4.89	169	0.704	0.025
	Negative Scale	239	-2.14	6.65	70	-1.15	6.29	169	0.226	0.078
	General Psychopathology scale	239	-3.59	9.14	70	-2.44	8.1	169	0.241	0.076
Perphenazine	Total score	200	-9.33	18.9	49	-0.13	16.89	151	0.002	0.215
	Positive Scale	200	-2.04	6.8	49	-0.36	5.94	151	0.209	0.089
	Negative Scale	200	-2.65	6.25	49	-0.23	5.28	151	0.006	0.196
	General Psychopathology scale	200	-4.63	9.5	49	0.46	9.11	151	0.002	0.216
Quetiapine	Total score	246	-1.74	14.86	57	0.15	79.9	189	0.556	0.038
	Positive Scale	247	-0.63	4.02	57	0.44	6.34	190	0.375	0.057
	Negative Scale	247	-0.56	5.85	57	-0.31	6.01	190	0.634	0.003
	General Psychopathology scale	246	-0.54	8.05	57	0.02	9.36	189	0.707	0.024
Risperidone	Total score	253	0.88	17.84	69	-2.71	19.87	184	0.092	-0.106
	Positive Scale	254	0.76	6.03	70	-0.8	6.07	184	0.056	-0.120
	Negative Scale	254	-0.03	6.4	70	-0.22	6.65	184	0.778	-0.018
	General Psychopathology scale	253	0.77	10.02	69	-1.68	10.28	184	0.064	-0.117
Ziprasidone	Total score	166	0.13	19.67	38	1.41	16.53	128	0.958	0.004
	Positive Scale	166	1.11	8.04	38	-0.02	5.73	128	0.275	-0.085
	Negative Scale	166	-0.55	5.94	38	0.54	5.34	128	0.324	0.077
	General Psychopathology scale	166	-0.42	8.21	38	1.07	8.81	128	0.678	0.032

PANSS: Positive and Negative Syndrome Scale; SD: standard deviation

¹ *p*-values and effect sizes associated with Mann-Whitney U tests